ACADIA Pharmaceuticals Inc.
This 52-week, open-label extension study is to evaluate the long-term safety and tolerability of ACP-204 in subjects with ADP.
Inclusion Criteria: * Subject has successfully completed ACP-204-006 study * Male or female (age 55 to 95 years old): female must be of non-childbearing potential, male must take appropriate contraceptive method if partner has childbearing potential * Subject has a designated study partner/caregiver * Subjects are able to complete all study visits with a study partner/caregiver * Signed inform consent form with a caregiver or legal representative Exclusion Criteria: * Requires treatment with a medication prohibited by the protocol * Is in hospice and receiving end-of-life palliative care, o…
ACP-204 30 mg given once daily, as capsule OR ACP-204 60 mg given once daily, as capsule